|1||NCT01082926||Completed||Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2||
||6||All||18 Years to 70 Years (Adult, Older Adult)||NCT01082926||07082
|May 2010||September 2013||September 2013||March 9, 2010||June 8, 2015||
|2||NCT00014573||Completed||Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer||
||Other / NIH||
||All||up to 65 Years (Child, Adult, Older Adult)||NCT00014573||CDR0000068559
|August 1998||October 2004||October 2004||April 5, 2004||April 8, 2013||
† Study has passed its completion date and status has not been verified in more than two years.